Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma

Authors: Ting Liu, Zeyuan Lei, ZhengYing Pan, Yu Chen, Xiang Li, TongChun Mao, Qian He, Dongli Fan

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

This study was designed to obtain a conclusive result about the relevance of p53 codon 72 polymorphism to the risk of cutaneous squamous cell carcinoma (SCC). We performed an updated meta-analysis of 3,792 subjects (1,349 cancer cases and 2,443 controls) to summarize the data available for p53 codon 72 polymorphism and SCC risk. The association was estimated by odds ratios (ORs) with 95 % confidence intervals (CIs). The meta-analysis showed no statistical significance for SCC risk associated with any of the genetic models of p53 codon 72 polymorphism. The analyses by ethnic subgroup also failed to produce significant associations. This study suggests that p53 codon 72 polymorphism does not appear to represent a significant susceptibility factor for SCC in Caucasians.
Literature
1.
Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 Pt 1):774–8.PubMedCrossRef
2.
Mueller CS, Reichrath J. Histology of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:215–26.PubMedCrossRef
3.
4.
5.
6.
Tilli CM et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005;152(6):1108–24.PubMedCrossRef
7.
8.
9.
10.
Thomas M et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092–100.PubMedCentralPubMed
11.
Dumont P et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.PubMedCrossRef
12.
Henner WD et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 2001;49(4):263–6.PubMedCrossRef
13.
Wu X et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94(9):681–90.PubMedCrossRef
14.
Fan R et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1037–42.PubMed
15.
Soulitzis N et al. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179(2):175–83.PubMedCrossRef
16.
Shen H et al. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183(2):123–30.PubMedCrossRef
17.
Helland A et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396(6711):530–1. author reply 532.PubMedCrossRef
18.
19.
Dokianakis DN et al. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5(4):405–9.PubMed
20.
Marshall SE et al. p53 codon 72 polymorphism and susceptibility to skin cancer after renal transplantation. Transplantation. 2000;69(5):994–6.PubMedCrossRef
21.
Bastiaens MT et al. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog. 2001;30(1):56–61.PubMedCrossRef
22.
Cairey-Remonnay S et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol. 2002;118(6):1026–31.PubMedCrossRef
23.
McGregor JM et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol. 2002;119(1):84–90.PubMedCrossRef
24.
Gustafsson AC et al. The role of p53 codon 72 and human papilloma virus status of cutaneous squamous cell carcinoma in the Swedish population. Acta Derm Venereol. 2004;84(6):439–44.PubMedCrossRef
25.
Han J et al. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog. 2006;45(9):694–700.PubMedCrossRef
26.
Bendesky A et al. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res. 2007;619(1–2):38–44.PubMedCrossRef
27.
Almquist LM et al. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis. 2011;32(3):327–30.PubMedCentralPubMedCrossRef
28.
Loeb KR et al. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One. 2012;7(4):e34422.PubMedCentralPubMedCrossRef
29.
Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRef
30.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
31.
32.
33.
Jiang DK et al. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol. 2011;131(1):220–8.PubMedCrossRef
Metadata
Title
Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma
Authors
Ting Liu
Zeyuan Lei
ZhengYing Pan
Yu Chen
Xiang Li
TongChun Mao
Qian He
Dongli Fan
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1518-0

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients

Research Article

A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility

Research Article

Clinical significance of S100A2 expression in gastric cancer

Research Article

N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy

Research Article

Genome-wide pathway analysis in neuroblastoma

Research Article

S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits